• search

Glaxo wins EU approval for Relenza to prevent flu

Written by: Staff

LONDON, Aug 24 (Reuters) GlaxoSmithKline Plc said today it had received approval in 15 European countries for use of its antiviral drug Relenza in the prevention of influenza types A and B.

The move means European governments can consider the drug for stockpiling in the event of a flu pandemic, which experts fear could be triggered by the current outbreak of bird flu.

Approval was also given for Relenza to be used as a treatment of flu in children 5 years of age and above.

Previously, Relenza, an inhaled medicine, had only been approved in Europe for treating flu in adults and children aged 12 years and above.

The medicine had already won US clearance as a preventative therapy in March this year.

''This approval is a significant step forward as it provides the medical community in Europe with another option to prevent and treat seasonal influenza, enabling governments to prepare for a potential flu pandemic,'' said David Stout, Glaxo's head of pharmaceutical operations.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more